Start-Up

After Selling 2 Cardiovascular Companies for Over $1 Billion, Duke Rohlen is Now Hoping to do the Same with Spirox and Advanced Cardiac Therapeutics

Jack Dorsey received quite a bit of attention when he was recently announced as CEO of Twitter.  Why?  Because that made him CEO of 2 of the most rapidly-growing tech. companies in Silicon Valley at the same – Twitter and Square.

Well, medtech’s version of Jack Dorsey might be Duke Rohlen.  Duke led FoxHollow Technologies through an IPO and then later solid it to ev3 for close to $800M.  He also founded CV Ingenuity and sold it to Covidien for approximately $300M.  Now, similar to Jack Dorsey, Duke is leading 2 early stage companies at the same time – Spirox and Advanced Cardiac Therapeutics.

In this interview with Duke Rohlen, CEO of both Spirox and Advanced Cardiac Therapeutics, we learn about the strategies and tactics he employed that led to the successful exits of FoxHollow Technologies and CV Ingenuity for a combined total of over $1 billion

Interview Highlights with Duke Rohlen

  • Why Duke and the CV Ingenuity team felt bittersweet after selling to Covidien for $300M.
  • Why the CV Ingenuity team pursued a US-only strategy.
  • Why CV Ingenuity managed their clinical trials internally vs. working with an outside CRO.
  • Duke’s previous relationships with the leadership at ev3 (now Medtronic) and why they were critical to closing the CV Ingenuity deal with Covidien.
  • How Duke secured a unique $300M collaboration with Merck while serving as President of Fox Hollow Technologies.
  • The major lessons Duke has learned raising money for 4 different medical device companies.
  • How Duke is able to successfully lead two early-stage medtech companies at the same time.
  • Duke’s favorite book, the CEO he’s closely following right now, and the advice he’d give to his 30-yr. old self.

Listen to the Interview with Duke Rohlen

Read the Interview with Duke Rohlen

Download a copy of the interview transcript right here.

About Duke Rohlen

Duke Rohlen serves as Chairman and CEO of Spirox, Inc. and Chairman and CEO of Advanced Cardiac Therapeutics.  Prior to these roles, Duke served as founder and CEO of CV Ingenuity where he raised $30.0 million of venture capital prior to selling the company to Covidien (now Medtronic) in 2013 for ~$300.0 million. Prior to CV Ingenuity, Duke served in a variety of roles at FoxHollow Technologies prior to being named President. Duke helped drive annual sales to ~$200.0 million, helped the company through an IPO, conceived of and structured a $300.0 million collaboration with Merck Pharmaceuticals, and ultimately led the sale of the company to EV3 (now Medtronic) for $780.0 million in 2008. Prior to working at FoxHollow, Duke held senior management positions at two other medical technology companies and served as an entrepreneur-in-residence at the private equity firm, Alta Partners.

You May Like These Articles

  • Recent
  • Featured
  • Related

The Importance of Understanding Clinical Trial Design as a Medtech CEO: Interview with Nadim Yared, CEO of CVRx

In this interview with Nadim Yared, CEO of CVRx, we discuss his journey with the company, including Nadim’s expertise on clinical trial strategy, startup funding, and working with FDA & CMS.

3 Critical Goals Every New Medical Device Should Aim For: Interview with Doug Evans, CEO of Lungpacer Medical

In this interview with Doug Evans, CEO of Lungpacer Medical, we discuss tips for launching medtech startups, working with payers & regulators, commercializing novel technologies, and we'll learn more about Lungpacer's impressive system.

Why Medtech Founders Should Not Over-Focus on Dilution: Interview with Renee Ryan, CEO of Cala Health

In this interview with Renee Ryan, CEO of Cala Health, we discuss some common mistakes that medtech startups make, and talk about what she looks for as an investor in early-stage companies. She also shares tips on navigating the regulatory waters and obtaining insurance coverage & reimbursement.

The Biggest Mistakes to Avoid When Designing Medical Device Prototypes: Interview with Mike Wallace, CEO of DeVoro Medical

In this interview with Mike Wallace, CEO of DeVoro Medical, he tells about the mistakes medtech entrepreneurs often make in the early stages of their companies and how you can pivot when an idea doesn’t pan out.

Conquering the Coverage and Reimbursement Landscape: Interview with Bruce Shook, President of Intact Vascular

In this interview, Bruce Shook discusses medical device insurance coverage and reimbursement, as well as advice for other healthcare entrepreneurs that need to raise money.

Why Curiosity and Persistence are Crucial Characteristics for Medtech Entrepreneurs: Interview with the Legendary Dr. John Simpson, Executive Chairman of Avinger

In this interview, the legendary Dr. John Simpson shares what drew him to the field of cardiology, his approach to building a medtech team, and why knowing your strengths and limitations is key to making a difference in the lives of others.

After Selling 2 Cardiovascular Companies for Over $1 Billion, Duke Rohlen is Now Hoping to do the Same with Spirox and Advanced Cardiac Therapeutics

In this interview with Duke Rohen, he discusses how he successfully led two early-stage medtech companies at the same time and the major lessons he learned raising money for 4 different medical device companies.

Having a Heart Attack? There’s an App for That! The Incredible Story of How Dr. David Albert Brought the ECG iPhone App to Market

In this interview with Dr. David Albert, we learn about his incredible journey in bringing the first iPhone ECG app to market with AliveCor.

The Importance of Understanding Clinical Trial Design as a Medtech CEO: Interview with Nadim Yared, CEO of CVRx

In this interview with Nadim Yared, CEO of CVRx, we discuss his journey with the company, including Nadim’s expertise on clinical trial strategy, startup funding, and working with FDA & CMS.

3 Critical Goals Every New Medical Device Should Aim For: Interview with Doug Evans, CEO of Lungpacer Medical

In this interview with Doug Evans, CEO of Lungpacer Medical, we discuss tips for launching medtech startups, working with payers & regulators, commercializing novel technologies, and we'll learn more about Lungpacer's impressive system.

Why Medtech Founders Should Not Over-Focus on Dilution: Interview with Renee Ryan, CEO of Cala Health

In this interview with Renee Ryan, CEO of Cala Health, we discuss some common mistakes that medtech startups make, and talk about what she looks for as an investor in early-stage companies. She also shares tips on navigating the regulatory waters and obtaining insurance coverage & reimbursement.

The Biggest Mistakes to Avoid When Designing Medical Device Prototypes: Interview with Mike Wallace, CEO of DeVoro Medical

In this interview with Mike Wallace, CEO of DeVoro Medical, he tells about the mistakes medtech entrepreneurs often make in the early stages of their companies and how you can pivot when an idea doesn’t pan out.

Success! Your membership is now active.